Section of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Clin Exp Rheumatol. 2012 Nov-Dec;30(6):838-42. Epub 2012 Dec 17.
Previous studies of intravenous immunoglobulin (IVIG) treatment in sporadic inclusion body myositis (sIBM) have yielded conflicting results. Here, we have undertaken a retrospective assessment of the long-term effects of IVIG in our sIBM cohort.
Sixteen sIBM patients, treated with a mean of 10 IVIG infusions and followed up for a mean period of 23 months, were identified. Six sIBM patients treated with other drugs were used as an internal control group. Serial data on manual muscle testing (MMT), laboratory parameters and patients' subjective assessment were collected.
Serial MMT scores were available in 14 IVIG treated patients. Two of these patients improved more than 20% in MMT from baseline up to the third IVIG infusion. One of six patients in the control group showed a similar MMT improvement during the first six months. Improved swallowing function was reported by three IVIG-treated patients, but none of the controls. The serum levels of creatine kinase fell more than 20 % after the first IVIG infusion in 7/16 IVIG-treated patients, but this improvement was not sustained during the follow-up period.
IVIG treatment appears to have short-term beneficial effects on muscle strength and dysphagia in some few sIBM patients, but these effects are not sustained over time.
既往关于静脉注射免疫球蛋白（IVIG）治疗散发性包涵体肌炎（sIBM）的研究结果相互矛盾。在此，我们对我们的 sIBM 患者队列中 IVIG 的长期疗效进行了回顾性评估。
我们确定了 16 例接受 IVIG 治疗（平均 10 次输注）、随访平均 23 个月的 sIBM 患者。选择了 6 例接受其他药物治疗的 sIBM 患者作为内部对照组。收集了关于徒手肌肉测试（MMT）、实验室参数和患者主观评估的连续数据。
14 例接受 IVIG 治疗的患者提供了连续的 MMT 评分。其中 2 例患者从基线到第三次 IVIG 输注时 MMT 评分提高了 20%以上。对照组 6 例患者中有 1 例在头 6 个月内出现类似的 MMT 改善。3 例接受 IVIG 治疗的患者报告吞咽功能改善，但对照组没有。16 例接受 IVIG 治疗的患者中有 7 例在首次 IVIG 输注后血清肌酸激酶水平下降超过 20%，但在随访期间并未持续改善。
IVIG 治疗似乎对少数 sIBM 患者的肌肉力量和吞咽困难有短期的有益影响，但这些效果并不能持续。
